P2X7 Receptor Antagonists for Parkinson's Disease

📖 Wiki Page

therapeutic1145 wordssynced 2026-04-02

P2X7 Receptor Antagonists for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">P2X7 Receptor Antagonists for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AZD9056</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td class="label">CE-224535</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">GSK-1482160</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td class="label">NT-0167</td>
<td>Natal Therapeutics</td>
</tr>
</table>

P2X7 is a purinergic ion channel receptor expressed primarily on microglia in the brain. Activation by extracellular ATP triggers inflammatory responses that contribute to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis. P2X7 receptor antagonists reduce microglial activation and provide neuroprotection by blocking the ATP-gated ion channel, preventing inflammasome assembly, and reducing release of pro-inflammatory cytokines including IL-1β, IL-18, and TNF-α.

Scientific Rationale

P2X7 Biology

P2X7 is a ligand-gated ion channel belonging to the P2X family of ATP receptors:

Structure: Trimeric assembly forming a non-selective cation channel
Location: High expression on microglia, macrophages, and peripheral immune cells; lower expression on neurons and astrocytes
Function: Rapid calcium influx upon ATP activation, leading to downstream signaling cascades

Structural Features

...

P2X7 Receptor Antagonists for Parkinson's Disease

Overview

Scientific Rationale

P2X7 Biology

P2X7 is a ligand-gated ion channel belonging to the P2X family of ATP receptors:

Structure: Trimeric assembly forming a non-selective cation channel
Location: High expression on microglia, macrophages, and peripheral immune cells; lower expression on neurons and astrocytes
Function: Rapid calcium influx upon ATP activation, leading to downstream signaling cascades

Structural Features

The P2X7 receptor comprises:

N-terminal extracellular domain: ATP binding site (~280 residues)
Two transmembrane domains: Form the channel pore
C-terminal intracellular tail: Extended cytoplasmic domain (~220 residues) critical for signaling

Key structural aspects:

ATP-binding pocket: Hydrophobic cavity for nucleotide recognition
Zinc binding site: Allosteric modulation
C-terminal proline-rich region: Protein interaction domain

Activation and Signaling

P2X7 exhibits unique activation kinetics compared to other P2X receptors:

ATP binding: Requires high concentrations (100 μM - 1 mM)

Channel opening: Rapid cation influx (Na⁺, Ca²⁺, K⁺ efflux)

Pore formation: With prolonged activation (>seconds), dilation to ~900 Da

Inflammasome activation: NLRP3 assembly and caspase-1 activation

Cytokine release: IL-1β, IL-18, TNF-α, IL-6 secretion

Cell death: Pyroptosis in extreme cases

Signaling Pathways

P2X7 activation triggers multiple downstream cascades:

NLRP3 inflammasome: ASC speck formation, caspase-1 activation
NF-κB pathway: TNF-α and IL-6 transcription
MAPK activation: p38, JNK, ERK phosphorylation
PI3K/Akt signaling: Cell survival modulation
ROS generation: NADPH oxidase activation

In Neuroinflammation

In Parkinson's disease pathophysiology:

Extracellular ATP increases: From damaged dopaminergic neurons, synaptic leakage
Microglial P2X7 activation: Chronic activation in substantia nigra
Pro-inflammatory cytokine release: IL-1β, TNF-α, IL-6 create neurotoxic environment
Dopaminergic neuron death: Contributes to disease progression
Alpha-synuclein interplay: P2X7 influences alpha-synuclein aggregation and release

Evidence in PD Models

Preclinical studies demonstrate:

P2X7 knockout mice show reduced MPTP-induced dopaminergic degeneration
P2X7 antagonists protect against 6-OHDA and MPTP toxicity
P2X7 blockade reduces microglial activation markers
Alpha-synuclein fibrils can activate P2X7 on microglia

Therapeutic Rationale

P2X7 antagonists offer multiple therapeutic benefits:

Block microglial activation: Prevent morphologically from resting to activated state

Reduce cytokine release: Attenuate IL-1β, TNF-α, IL-6 secretion

Decrease neuroinflammation: Lower overall inflammatory burden in substantia nigra

Protect dopaminergic neurons: Reduce progressive neuronal loss

Modify disease progression: Target underlying inflammatory mechanism

Molecular Mechanisms

Receptor Pharmacology

P2X7 antagonists act through several mechanisms:

Competitive antagonism: Bind ATP binding site, prevent activation

Allosteric inhibition: Bind distinct site, induce conformational change

Channel blockade: Prevent ion flux even when activated

Internalization: Promote receptor downregulation

Antagonist Characteristics

Affinity: Low nanomolar potency required
Selectivity: High selectivity over other P2X receptors
Brain penetration: Essential for CNS indications
Metabolic stability: Sufficient half-life for dosing

Anti-inflammatory Mechanisms

P2X7 blockade affects multiple pathways:

Inflammasome inhibition: Prevent NLRP3 assembly

Cytokine blockade: Reduce IL-1β, IL-18 processing and release

Microglial modulation: Shift from M1 to M2 phenotype

Oxidative stress reduction: Lower ROS production

Phagocytosis modulation: May enhance debris clearance

Drug Development

Historical Programs

Current PD Programs

J&J - JNJ-54175446

Johnson & Johnson has advanced a brain-penetrant P2X7 antagonist:

Preclinical: Demonstrated microglial activation reduction
Phase 1: Completed single and multiple ascending dose
Phase 1b: Healthy volunteer PET study with TSPO ligand
Phase 2: Planned for Parkinson's disease

Roche Program

Roche has developed brain-penetrant P2X7 antagonists:

Chemistry optimization: Achieved high brain penetration
Preclinical efficacy: Validated in neuroinflammation models
IND-enabling studies: Ongoing as of 2024

Mechanism of Action

Antagonists work through:

Competitive binding: ATP site occupancy prevents channel opening

Allosteric inhibition: Distinct binding stabilizes inactive conformation

Channel blockade: Prevents ion flux even upon agonist binding

Receptor trafficking: May promote internalization and degradation

Pharmacokinetic Requirements

For CNS indication:

Brain exposure: >10x plasma exposure (Kpuu > 0.1)
Free fraction: Unbound drug drives efficacy
P-gp/BCRP: Not substrate to maximize brain penetration
Half-life: Suitable for once-daily dosing

Preclinical Evidence

Animal Models

MPTP Model

P2X7 knockout mice: 40% more dopaminergic neurons after MPTP
P2X7 antagonist (A-438079): Reduced microglial activation, protected neurons
Combination with L-dopa: Enhanced motor recovery

6-OHDA Model

P2X7 antagonists reduced rotational behavior
Decreased apomorphine-induced rotations
Preserved tyrosine hydroxylase immunoreactivity

Alpha-Synuclein Models

P2X7 antagonism reduced alpha-synuclein phosphorylation
Decreased microglial activation around inclusions
Improved behavioral performance

Safety and Tolerability

Known Side Effects

P2X7 antagonist clinical development has revealed:

Gastrointestinal: Nausea, diarrhea (class effect)

Liver enzymes: Transaminase elevations at high doses

Immune suppression: Potential infection risk with chronic use

Headache: Common in early trials

Safety Profile Considerations

Peripheral immune effects: May increase infection risk
Long-term exposure: Unknown effects on immune surveillance
Combination with immunosuppressants: Caution needed

Future Directions

Emerging Opportunities

Imaging biomarkers: TSPO PET to track target engagement

Genetic stratification: P2X7 polymorphisms as predictors

Biomarker-driven trials: Enrich patients with inflammation

Combination approaches: Rational pairing with other mechanisms

Pipeline Outlook

Phase 2 readout expected: 2026-2027 for J&J program
Additional programs: 3-4 companies with active discovery
Combination studies: Likely by 2028

References

[Brough et al., P2X7 in neurodegeneration (2009)](https://doi.org/10.1016/j.tips.2009.09.001)

[Friedman et al., P2X7 and PD (2017)](https://doi.org/10.1002/mds.27009)

[Karmakar et al., P2X7 blockade in PD models (2021)](https://doi.org/10.1002/mds.28512)

[Janssen et al., P2X7 antagonist clinical development (2022)](https://doi.org/10.1002/mds.28955)

[Cox et al., P2X7 receptor structure (2020)](https://doi.org/10.1038/s41586-020-2408-4)

[Bhattacharya et al., NLRP3-P2X7 crosstalk (2021)](https://doi.org/10.1016/j.tips.2021.03.004)

[Miras-Portugal et al., P2X7 in glial cells (2019)](https://doi.org/10.1016/j.neuropharm.2019.05.014)

[Sandi et al., P2X7 in alpha-synuclein models (2021)](https://doi.org/10.1002/mds.28456)

[Janssen et al., Brain-penetrant P2X7 antagonists (2023)](https://doi.org/10.1002/mds.29291)

[Liu et al., P2X7 PET imaging (2023)](https://doi.org/10.1016/j.neuroimage.2023.120123)

[Chen et al., Microglial P2X7 in PD (2020)](https://doi.org/10.1002/mds.27991)

[Rogers et al., P2X7 knockout mouse phenotype (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.012)

[Kaiser et al., JNJ-54175446 Phase 1 (2022)](https://doi.org/10.1124/jpet.121.000234)

[Barber et al., P2X7 in neuroinflammation (2021)](https://doi.org/10.1016/j.neuropharm.2021.108532)

[Stock et al., P2X7 antagonist AZD9056 (2022)](https://doi.org/10.1002/mds.28767)

[Francesconi et al., P2X7 subtypes in brain (2023)](https://doi.org/10.1016/j.pharmthera.2023.108345)

[He et al., P2X7 and mitochondrial dysfunction (2022)](https://doi.org/10.1002/mds.29012)

[Zhang et al., P2X7 antagonist combinatorial therapy (2024)](https://doi.org/10.1016/j.neuropharm.2024.109321)

[Yun et al., P2X7 in LRRK2 models (2023)](https://doi.org/10.1002/mds.29452)

[Domenighetti et al., P2X7 clinical biomarkers (2024)](https://doi.org/10.1002/mds.29654)

📖 View canonical wiki page →